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In 2002, the European Science Foundation (ESF) published a Science Policy 
Briefing entitled Human Stem Cell Research: Scientific Uncertainties and Ethical 
Dilemmas. Since then there have been significant advances in the field of  
research, notably the emergence of regenerative medicine (RM) which promises to 
be a fascinating development, opening the possibility of repairing or replacing 
tissue or organ function lost due to age, disease, damage, or congenital defects 
using human stem cells (hSCs)—an approach that also raises ethical issues. 
 
The increase in chronic diseases and population ageing has led to an increasing 
demand for transplantation of organs such as liver, heart, lung, and kidney. There 
are currently 56,000 patients waiting for a suitable organ donor in the European 
Union (EU). Less invasive treatments, such as enabling regeneration of damaged 
heart tissue with hSCs, would help alleviate this problem. 
 
The European Medical Research Councils at the ESF established a High-Level 
Expert Group which made specific recommendations intended to stimulate 
continuing efforts by relevant stakeholders to ensure that SC research is 
developed into RM applications and other benefits for patients, when 
ensuring that research is conducted in accordance with accepted principles of 
ethics. With this article, the ESF aims to summarize the current scientific and 
ethical issues that surround hSC research in RM, review the current legislation 
landscape in Europe, and set out the position of the ESF on future priorities in this 
area. The new updated Science Policy Briefing ‘‘Human Stem Cell Research and 
Regenerative Medicine: a European Perspective on Scientific, Ethical and Legal 
Issues’’ has now been published by the ESF (ESF Science Policy Briefing 38. 16 
pp, ISBN 978-2-918428-12-1) and is available at: ww.esf.org/publications/science-
policy-briefings. 
 
Embryonic, induced pluripotent stem (iPS) cells, fetal, adult- and tissue-derived 
stem cells are all the focus of active research in European countries and 
elsewhere. All these different types of SCs have their own characteristics and are  
Important in research, representing potential sources of cells for clinical use. At this 
stage it would be premature to consider limiting any potential avenues of research. 
 
In August 2009, there were approximately 650 hESC lines worldwide and many of 
these (252 European and 349 non-European) are registered in the European 
Human Embryonic Stem Cell Registry (www.hescreg.eu) funded by the European 
Commission.  
 
The International Stem Cell Forum (ISCF), a 21-member organization (academies, 
research institutes and councils, foundations) has managed extensive projects 
such as the International Stem Cell Initiatives (ISCI) involving several European 
laboratories. ISCI1 aims to extensively characterize a larger number of hESC lines 
worldwide, whereas ISCI2, which addressed the culture conditions, is completed; 
ISCI3, exploring the genetic stability of hESCs, is underway. hESCs 
also provide methods to evaluate disease mechanisms and high-throughput 
screening of new compounds for drug development. 
 
The use of somatic cell nuclear transfer (SCNT) to obtain patient-specific SC lines 
has been superseded in European laboratories by the introduction of the new 
promising alternative of reprogramming somatic cells to pluripotency using defined 
factors (iPS cells). There is now intensive research worldwide to develop methods 
for inducing pluripotency to achieve safe iPS cells for cell transplantation in clinical 
trials. iPS cells already represent a unique route for drug development and for 
studying inherited or environment- and age-related human diseases. 
 
The EU Tissues and Cells Directive (EUTCD, 
http://ec.europa.eu/health/ph_threats/human_substance/legal_tissues_cells_en.ht
m) regulates the quality of all cells used in human therapy including hSCs and 
requires Good Manufacturing Practice-based production systems for clinical 
applications. Additional requirements in terms of quality of procedures and 
cleanliness of products exist in the case of hSCs. 
 
Adult- and tissue-derived stem cells are already being used clinically, for example, 
hematopoietic SCs for bone marrow transplants since 1968. However, SCs derived 
from adult tissues such as the skin, adipose tissue, and bone marrow are 
still at an early-stage of evaluation in clinical trials. Mesenchymal stem cells 
(MSCs) are the most popular type of adult SCs for these clinical applications and 
the type of adult SC that is expected to reach clinics next. The websites of the 
European Community EudraCT (https://eudract.emea.europa.eu/) and of the US 
National Institutes of Health (www.ClinicalTrials. gov) provide information on the 
107 current clinical trials based on the use of MSCs. Eight of these trials are in 
phase III as of April 2010, but only one (just completed) testing the use of MSCs in 
graft-versus-host-disease involved European clinical centers, in Italy, U.K., and 
Spain. However, European involvement is much higher in phase I/II clinical trials, 
most of these being investigator-driven (not industry-driven) trials: 25 of the 82 
current phase I/II trials using MSCs are based in 12 different  European countries 
(Belgium, Denmark, Italy, Germany, the Netherlands, Norway, Spain, U.K., France, 
Finland, Ireland, Slovenia). Therapeutic indications of ongoing clinical trials using 
adipose-derived SCs include steroid-refractory graft-versus-host disease,  
periodontitis, severe chronic myocardial ischemia, distal tibia fracture, 
osteoarthritis, decompensated liver cirrhosis, multiple sclerosis, tumor-induced 




The ESF Forward Look Investigator-Driven Clinical Trials (http://www.esf.org/idct) 
makes recommendations on the conduct of clinical trials, most of these being 
applicable to the hSC research field, such as the need for harmonizing the mission 
and role of ethics committees and increasing the ethical standards of clinical trials, 
and the need for fully exploiting the knowledge produced by new medical 
breakthroughs. 
 
Safety aspects, such as tumor formation, immunogenicity, epigenetic status, and 
stability, are the major current issues facing the clinical use of all types of hSCs 
worldwide. 
 
Ethical and legal issues are crucial in Europe. In most European countries ethical 
approval and informed written consent of the patient are required for all use of 
human cells and tissues. Consent is the central focus of legislation relating to 
access to identifiable patient data and use of identifiable tissue for research 
(http://www.wma.net/en/30publications/10policies/b3/index.html). All donors must 
be fully informed in writing, in particular, about the aims of the research and any 
potential commercial interest. 
 
Advanced Therapies refers to Regulation European Comission (EC) No 1394/2007 
on Advanced Therapy Medicinal Products that will bring gene, cellular, and tissue-
based therapies together within a single, integrated European regulatory 
framework. This regulation was formally adopted by the EU Council and entered 
into force on December 30, 2007. The implementation plan has been agreed with 
the European Medicines Agency. 
 
Patenting hESCs at the European Patent Office (EPO) has proved to be a difficult 
process as national states implement different policies on the topic of human 
embryonic stem cells (hESC) research. The European Patent Convention (EPC) 
regulates the granting of patents (examination, issuance) but the legal effects 
(validity, infringement) of a patent fall under national jurisdiction. The EPC prohibits 
hESC patentability on ethical grounds for inventions whose ‘‘exploitation or 
publication would be contrary to ordre public or morality.’’ Furthermore, the EPC 
does not allow patenting on ‘‘uses of human embryos for industrial or commercial 
purposes’’ (EPC: ‘‘Under Article 53.(a), European patents shall not be granted in 
respect of biotechnological inventions which, in particular, concern the following: 
[.…](c) uses of human embryos for industrial or commercial purposes.’’) [4–6]. 
Nonetheless, the current EPO approach to patenting hESCs in Europe requires 
a revision to adapt to the fast development of SC technologies, an issue that 
European leaders should address quickly. 
 
Legislation Across Europe 
 
One of the recommendations from the previous 2001 and 2002 editions of the ESF 
Science Policy Briefing Human Stem Cell Research: Scientific Uncertainties and 
Ethical Dilemmas was to update the table of regulations on the use of 
hSCs in the 30 ESF membership countries (see Annex 1 of the ESF Science 
Policy Briefing 38, data from http://www.hescreg.eu/index.php?id¼8 and 
http://www.isscr.org/public/regions/region.cfm?RegionID¼1). In summary, 25 
countries have adopted legislation which explicitly prohibits human reproductive 
cloning (excluding Poland, Lithuania, Ireland, Croatia, and Luxembourg). Seven 
countries allow hESC research and the derivation of new hESC lines from 
supernumerary in vitro fertilization embryos by law (Belgium, Sweden, U.K., Spain, 
Finland, the Czech Republic and Portugal). The same countries allow SCNT by law 
except Finland and the Czech Republic who neither prohibit nor allow it. Three 
countries have adopted legislation to allow the creation of embryos for research 
purposes under strict conditions (Belgium, Sweden, U.K.). Currently, 17 countries 
allow the procurement of SCs from supernumerary embryos and six countries have 
not adopted legislation regarding hSC research (Bulgaria, Croatia, Cyprus, 
Luxembourg, Romania, and Turkey). This ever expanding field needs constant 
updating of legislation and new thinking on the ethical questions that arise. For 
instance, there are different ethical aspects to be considered in iPS cell research 
compared with hESC research. 
 
Seven Statements and Recommendations Were Made by the ESF Working 
Group 
 
1. Continued research on all types of SCs derived from embryos, fetal tissues, and 
adults remains necessary as it is too early to predict their value in a specific field. 
Research using embryonic and iPS cells are required, as the knowledge derived 
from both is complementary and for the moment the benefits and risks are not 
sufficiently known. 
 
2. Although clinical research is clearly important, basic research remains essential 
to understand cellular differentiation and function. 
 
3. The lack of common criteria and universal standards for the preparation of SCs 
has greatly hampered further progress. Furthermore, functional characterization of 
SCs is limited by the available methods for in vitro differentiation. There is an 
urgent need for a comprehensive understanding of SC identity and characteristics. 
 
4. Progress toward therapies would be faster if researchers across Europe were 
given equitable research opportunities provided that balanced facts about the risks 
and benefits of research are understood. If therapies become available, all patients 
across Europe should have equitable access to such therapies. 
 
5. In view of safety concerns relating to SCs in clinical applications, chemically 
defined animal substance-free products and standard operational procedures 
(SOPs) should be further developed and implemented. Aspects including proof 
of functionality, safety, quality control, storage, and banking need to be addressed 
before therapy enters the market. 
  
6. More studies about the immunogenicity, epigenetic status and stability of SCs, 
and the immune response of the human organism are needed. 
 
7. Public funding, including at the European level, is necessary to support the 
translation and implementation of SCbased products into the market. 
 
FUTURE OF STEM CELL RESEARCH IN EUROPE 
 
SC research in Europe has proceeded at a rapid pace over the past decade with a 
high level of science being maintained in a field that has become globally 
competitive. Provided that adequate funding is maintained and unresolved issues 
surrounding patents are addressed, there is hope that new treatments for many 
severe diseases could emerge. SCs offer the opportunity for the revolutionary 
therapy and medical challenge of the 21st century, a challenge that needs to be 
met by the EU based on ethical principles that may differ between European 
countries, on respect for human rights both within and outside EU frontiers, and on 
the intellectual integrity that has built the identity and democracy of today’s Europe. 
 
 
